Latest Pharma Insights
Kenvue Continues Growth Before K-C Acquisition
With close of Kimberly-Clark acquisition approaching, Kenvue announces third-quarter results of 3.2% growth to $3.89bn revenues, with organic sales up 2.9%, on 1.6% volume growth and 1.3% from pricing.
HBW Insight - November 2, 2026
With close of Kimberly-Clark acquisition approaching, Kenvue announces third-quarter results of 3.2% growth to $3.89bn revenues, with organic sales up 2.9%, on 1.6% volume growth and 1.3% from pricing.
HBW Insight - November 2, 2026
C&D Touches Up Touchland Expectations, Still Cautious On Touching Prices Due To Inflation
Although Touchland, available in distinctive packaging and scents, “kind of created a category that didn't really exist,” says C&D CEO Richard Dierkerm competition emerged from b.pure brand at retail chain C&D hasn’t reached.
HBW Insight - November 2, 2026
Although Touchland, available in distinctive packaging and scents, “kind of created a category that didn't really exist,” says C&D CEO Richard Dierkerm competition emerged from b.pure brand at retail chain C&D hasn’t reached.
HBW Insight - November 2, 2026
Illumina Lifts 2026 Outlook As NovaSeq X Placements Rise But Instrument Revenue Slips
Illumina raised its 2026 revenue and EPS guidance after clinical demand and 80-plus NovaSeq X placements lifted third-quarter results above forecast. But instrument revenue was held back by discounting and leasing, leaving consumables to carry the case for high-single-digit growth in 2027.
Medtech Insight - November 2, 2026
Illumina raised its 2026 revenue and EPS guidance after clinical demand and 80-plus NovaSeq X placements lifted third-quarter results above forecast. But instrument revenue was held back by discounting and leasing, leaving consumables to carry the case for high-single-digit growth in 2027.
Medtech Insight - November 2, 2026
FDA Issues Revised Draft Guidance On Essential Drug Delivery Performance Characteristics
Revised draft guidance from US FDA’s Office of Combination Products and its drug, device and biologics centers recommends how sponsors should identify, verify and control the system-level characteristics meant to ensure a drug-device product delivers the intended dose.
Medtech Insight - November 2, 2026
Revised draft guidance from US FDA’s Office of Combination Products and its drug, device and biologics centers recommends how sponsors should identify, verify and control the system-level characteristics meant to ensure a drug-device product delivers the intended dose.
Medtech Insight - November 2, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.
Scrip - November 2, 2026
In this week's episode: US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.
Scrip - November 2, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.
Scrip - November 2, 2026
In this week's episode: US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.
Scrip - November 2, 2026
Illumina Lifts 2026 Outlook As NovaSeq X Placements Rise But Instrument Revenue Slips
Illumina raised its 2026 revenue and EPS guidance after clinical demand and 80-plus NovaSeq X placements lifted third-quarter results above forecast. But instrument revenue was held back by discounting and leasing, leaving consumables to carry the case for high-single-digit growth in 2027.
Medtech Insight - November 2, 2026
Illumina raised its 2026 revenue and EPS guidance after clinical demand and 80-plus NovaSeq X placements lifted third-quarter results above forecast. But instrument revenue was held back by discounting and leasing, leaving consumables to carry the case for high-single-digit growth in 2027.
Medtech Insight - November 2, 2026
FDA Issues Revised Draft Guidance On Essential Drug Delivery Performance Characteristics
Revised draft guidance from US FDA’s Office of Combination Products and its drug, device and biologics centers recommends how sponsors should identify, verify and control the system-level characteristics meant to ensure a drug-device product delivers the intended dose.
Medtech Insight - November 2, 2026
Revised draft guidance from US FDA’s Office of Combination Products and its drug, device and biologics centers recommends how sponsors should identify, verify and control the system-level characteristics meant to ensure a drug-device product delivers the intended dose.
Medtech Insight - November 2, 2026
Kenvue Continues Growth Before K-C Acquisition
With close of Kimberly-Clark acquisition approaching, Kenvue announces third-quarter results of 3.2% growth to $3.89bn revenues, with organic sales up 2.9%, on 1.6% volume growth and 1.3% from pricing.
HBW Insight - November 2, 2026
With close of Kimberly-Clark acquisition approaching, Kenvue announces third-quarter results of 3.2% growth to $3.89bn revenues, with organic sales up 2.9%, on 1.6% volume growth and 1.3% from pricing.
HBW Insight - November 2, 2026
C&D Touches Up Touchland Expectations, Still Cautious On Touching Prices Due To Inflation
Although Touchland, available in distinctive packaging and scents, “kind of created a category that didn't really exist,” says C&D CEO Richard Dierkerm competition emerged from b.pure brand at retail chain C&D hasn’t reached.
HBW Insight - November 2, 2026
Although Touchland, available in distinctive packaging and scents, “kind of created a category that didn't really exist,” says C&D CEO Richard Dierkerm competition emerged from b.pure brand at retail chain C&D hasn’t reached.
HBW Insight - November 2, 2026
What’s Next? Five Things To Look Out For In November
Generics Bulletin previews some of the most noteworthy and anticipated events on the way for the off-patent industry in November 2026.
Generics Bulletin - November 1, 2026
Generics Bulletin previews some of the most noteworthy and anticipated events on the way for the off-patent industry in November 2026.
Generics Bulletin - November 1, 2026
The Shift Toward Precision Immunology in Rheumatology Trials
How biomarker-driven strategies are reshaping patient selection, trial design and clinical development in autoimmune disease.
In Vivo - October 30, 2026
How biomarker-driven strategies are reshaping patient selection, trial design and clinical development in autoimmune disease.
In Vivo - October 30, 2026
Ophthalmology Has A Long History With AI, But Sees Modern Challenges
The AI ophthalmology market could be worth $1.3bn by 2030 as diagnosis, drug discovery and surgery all benefit from decades of innovation.
In Vivo - October 30, 2026
The AI ophthalmology market could be worth $1.3bn by 2030 as diagnosis, drug discovery and surgery all benefit from decades of innovation.
In Vivo - October 30, 2026